ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ)
$3.09 0.02 (0.6515%)
Analysed ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) News Sources
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
30-03-2026
yahoo.com
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
28-04-2026
yahoo.com
Rocket to sell PRV for $180m to advance gene therapy pipeline
29-04-2026
hospitalmanagement.net
3 Promising Penny Stocks With Market Caps Up To $600M
06-05-2026
yahoo.com
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
07-05-2026
yahoo.com
Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says
08-05-2026
yahoo.com
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
11-05-2026
yahoo.com
Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M
18-05-2026
yahoo.com
Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going?
20-05-2026
yahoo.com
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
28-05-2026
yahoo.com
What is the current price of ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ)?
The current price of ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) is $3.09.
ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) absolute price change since previous trading day?
The absolute price change of ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) since the previous trading day is $0.02.
ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) percentage price change since previous trading day?
The percentage price change of ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) since the previous trading day is 0.6515%.
What is the most recent average sentiment score for ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ)?
The most recent average sentiment score for ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) is 87 out of 100.
What is the most recent average sentiment for ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ)?
The most recent sentiment for ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) is .
SEC-8K** Filing Available For ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.